Caffeine and Resistance ExerciseCAF+VelNCT07701395
Acute Caffeine Intake and Velocity Metrics
A study testing Caffeine in people with Caffeine and Resistance Exercise, run by University of Alcala at 1 site in Spain.
Trial summary
The purpose of this study was to determine whether the acute ergogenic effects of caffeine differ according to the velocity metric used to assess strength performance against different relative loads. Thirteen resistance-trained men completed a triple-blind, randomized, placebo-controlled, crossover study. Read more about this study
- Who is it for?
- Ages 18 to 35 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Caffeine and Resistance Exercise
- What is being tested?
- Caffeine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 13 participants
- Where
- 1 siteSpain
- Study dates
- 1 Jan 2025to 1 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age between 18 and 35 years.
- Body Mass Index (BMI) < 25 kg/m².
- Resistance-trained individuals (more than 6 months of structured training).
- Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising.
- Participants must be able to perform the tests described in the following section.
Who cannot join
- History of neuromuscular diseases, heart disease, or conditions that may affect liver or muscle metabolism.
- Use of drugs, stimulants, or sports supplements that could interfere with the dietary supplement used in the study.
- Sedentary habits (less than 150 minutes/week of moderate exercise).
- Having undergone prolonged periods of physical inactivity in the 6 months prior to the study.
- Engaging in strenuous exercise within 48 hours prior to the tests.• Failure to replicate the same food intake on both experimental days.
- Consumption of caffeine or any other stimulant after 6 pm on the day before the tests, to avoid headaches, discomfort, or lethargy in regular caffeine consumers.
Trial locations and contacts
1 site in 1 country.
Spain1 site
Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
Alcalá de Henares, Madrid, 28805
About this study
Official title: Acute Caffeine Ingestion Similarly Enhances Mean and Mean Propulsive Velocity During Resistance Exercise in Trained Men
The purpose of this study was to determine whether the acute ergogenic effects of caffeine differ according to the velocity metric used to assess strength performance against different relative loads. Thirteen resistance-trained men completed a triple-blind, randomized, placebo-controlled, crossover study. Participants ingested either caffeine (3 mg·kg-1) or a placebo 60 min before performing bench press and back squat exercises at 25%, 50%, 75%, and 90% of one-repetition maximum (1RM). Mean velocity (MV) and mean propulsive velocity (MPV) were simultaneously recorded using a linear position transducer
- Conditions
- Caffeine and Resistance Exercise
- Being tested
- Caffeine, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CaffeineDietary supplement
Acute caffeine intake (3 mg·kg-1)
PlaceboDietary supplement
Acute placebo intake (3 mg·kg-1 of maltodextrin)
| Study group | Role | What they receive |
|---|---|---|
| Caffeine | Experimental | Acute caffeine intake (3 mg·kg-1) Receives: Dietary Supplement: Caffeine |
| Placebo | Placebo comparator | Acute placebo intake (3 mg·kg-1 of maltodextrin) Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Velocity metrics against different relative loads of one-repetition maximum
Measuring bar mean velocity (during propulsive and braking phases in m/s) and mean propulsive velocity (m/s of the propulsive phase) displacement of the concentric phase during bench press and back squat exercises at 25%, 50%, 75%, and 90%1RM.
Measured: Through study completion, an average of 3 weeks
Secondary outcomes (1)
Adverse effects
perception of power, endurance, energy and exertion, as well as heart, muscular and gastrointestinal discomfort were measured using a 5-point scale, with scores ranging from 1 (lowest perception or absence of symptoms) to 5 (highest perception or severity).
Measured: Through study completion, an average of 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start1 Jan 2025
- Primary completion1 Jun 2025
- Study completion1 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Caffeine and Resistance ExerciseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Alcala
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alberto Pérez-López, University of Alcala
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07701395
- Sponsor's protocol ID
- CEIP/2024/5/113
- Acronym
- CAF+Vel
- Status last verified
- Jul 2026
- First submitted
- 8 Jul 2026
- Last updated
- 15 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Acute Caffeine Ingestion Similarly Enhances Mean and Mean Propulsive Velocity During Resistance Exercise in Trained Men
- ClinicalTrials.gov ID
- NCT07701395
- Acronym / sponsor ID
- CAF+Vel / CEIP/2024/5/113
- Conditions
- Caffeine and Resistance Exercise
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- University of AlcalaUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 1 Jun 2025 (actual)
- Study completion
- 1 Dec 2025 (actual)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to determine whether the acute ergogenic effects of caffeine differ according to the velocity metric used to assess strength performance against different relative loads. Thirteen resistance-trained men completed a triple-blind, randomized, placebo-controlled, crossover study. Participants ingested either caffeine (3 mg·kg-1) or a placebo 60 min before performing bench press and back squat exercises at 25%, 50%, 75%, and 90% of one-repetition maximum (1RM). Mean velocity (MV) and mean propulsive velocity (MPV) were simultaneously recorded using a linear position transducer
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Caffeine | Experimental | Dietary Supplement: CaffeineAcute caffeine intake (3 mg·kg-1) |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboAcute placebo intake (3 mg·kg-1 of maltodextrin) |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Age between 18 and 35 years.
- Body Mass Index (BMI) < 25 kg/m².
- Resistance-trained individuals (more than 6 months of structured training).
- Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising.
- Participants must be able to perform the tests described in the following section.
Key exclusion criteria (6 listed)
- History of neuromuscular diseases, heart disease, or conditions that may affect liver or muscle metabolism.
- Use of drugs, stimulants, or sports supplements that could interfere with the dietary supplement used in the study.
- Sedentary habits (less than 150 minutes/week of moderate exercise).
- Having undergone prolonged periods of physical inactivity in the 6 months prior to the study.
- Engaging in strenuous exercise within 48 hours prior to the tests.• Failure to replicate the same food intake on both experimental days.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CaffeineAcute caffeine intake (3 mg·kg-1) | Dietary supplement | Caffeine |
| PlaceboAcute placebo intake (3 mg·kg-1 of maltodextrin) | Dietary supplement | Placebo |
Primary outcome
Velocity metrics against different relative loads of one-repetition maximum
Time frame: Through study completion, an average of 3 weeks
Measuring bar mean velocity (during propulsive and braking phases in m/s) and mean propulsive velocity (m/s of the propulsive phase) displacement of the concentric phase during bench press and back squat exercises at 25%, 50%, 75%, and 90%1RM.
1 secondary outcome
Adverse effects
Time frame: Through study completion, an average of 3 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2026.
- Individual participant dataSharing planned: Yes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Caffeine in people with Caffeine and Resistance Exercise, run by University of Alcala at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Velocity metrics against different relative loads of one-repetition maximum (time frame: Through study completion, an average of 3 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026.